Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith Borcoman

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 19, 2021
Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynxCaroline Hoffmann, Valentin Calugaru, Edith Borcoman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2020
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckChristophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, et al.
Clinical and Translational Science|March 20, 2021
Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancerCarlos Gomez-Roca, Caroline Even, Christophe Le Tourneau, et al.
Cancers|November 6, 2019
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-AnalysisJong Yeob Kim, Keum Hwa Lee, Jeonghyun Kang, et al.
Oncoimmunology|May 12, 2025
CD8<sup>+</sup> T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevanceCarolina Abrate, Fernando P Canale, Sabrina N Bossio, et al.
Critical Care Medicine|April 23, 2020
Sepsis and Septic Shock in Patients With Malignancies: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique StudyVirginie Lemiale, Stéphanie Pons, Adrien Mirouse, et al.
Scientific Reports|April 13, 2021
Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patientsCindy Neuzillet, Manon Marchais, Sophie Vacher, et al.
Oncoimmunology|October 27, 2023
CD39<sup>+</sup> conventional CD4<sup>+</sup> T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockadeSabrina N Bossio, Carolina Abrate, Jimena Tosello Boari, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2019
Immune gene expression in head and neck squamous cell carcinoma patientsCharlotte Lecerf, Maud Kamal, Sophie Vacher, et al.
British Journal of Cancer|August 26, 2020
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumoursChristophe Le Tourneau, Jean-Pierre Delord, Nuria Kotecki, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|February 19, 2021
Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynxCaroline Hoffmann, Valentin Calugaru, Edith Borcoman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2020
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckChristophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, et al.
Clinical and Translational Science|March 20, 2021
Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancerCarlos Gomez-Roca, Caroline Even, Christophe Le Tourneau, et al.
Cancers|November 6, 2019
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-AnalysisJong Yeob Kim, Keum Hwa Lee, Jeonghyun Kang, et al.
Oncoimmunology|May 12, 2025
CD8<sup>+</sup> T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevanceCarolina Abrate, Fernando P Canale, Sabrina N Bossio, et al.
Critical Care Medicine|April 23, 2020
Sepsis and Septic Shock in Patients With Malignancies: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique StudyVirginie Lemiale, Stéphanie Pons, Adrien Mirouse, et al.
Scientific Reports|April 13, 2021
Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patientsCindy Neuzillet, Manon Marchais, Sophie Vacher, et al.
Oncoimmunology|October 27, 2023
CD39<sup>+</sup> conventional CD4<sup>+</sup> T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockadeSabrina N Bossio, Carolina Abrate, Jimena Tosello Boari, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2019
Immune gene expression in head and neck squamous cell carcinoma patientsCharlotte Lecerf, Maud Kamal, Sophie Vacher, et al.
British Journal of Cancer|August 26, 2020
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumoursChristophe Le Tourneau, Jean-Pierre Delord, Nuria Kotecki, et al.
Pageof 6